Our data showed that downregulation of DDX52 expression suppresses cell proliferation and causes significant regression of established tumors in nude mice by targeting c-Myc, suggesting that DDX52 is as a novel therapeutic target for the management of MM. This evidence concerns the gene DDX52 and Miyoshi myopathy.